keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/28918544/tumor-regression-grading-of-gastrointestinal-cancers-after-neoadjuvant-therapy
#1
REVIEW
Rupert Langer, Karen Becker
Neoadjuvant therapy has been successfully introduced in the treatment of locally advanced gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The effects of preoperative chemo- or radiochemotherapy can be determined by histopathological investigation of the resection specimen following this treatment. Frequent histological findings after neoadjuvant therapy include various amounts of residual tumor, inflammation, resorptive changes with infiltrates of foamy histiocytes, foreign body reactions, and scarry fibrosis...
September 16, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28916945/simvastatin-enhances-radiation-sensitivity-of-colorectal-cancer-cells
#2
Georgios Karagkounis, Jennifer DeVecchio, Sylvain Ferrandon, Matthew F Kalady
INTRODUCTION: Neoadjuvant chemoradiation (CRT) for rectal cancer induces variable responses, and better response has been associated with improved oncologic outcomes. Our group has previously shown that the administration of HMG-CoA reductase inhibitors, commonly known as statins, is associated with improved response to neoadjuvant CRT in rectal cancer patients. The purpose of this study was to study the effects of simvastatin on colorectal cancer cells and explore its potential as a radiation-sensitizer in vitro...
September 15, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28916906/neoadjuvant-versus-definitive-chemoradiotherapy-for-locally-advanced-esophageal-cancer-outcomes-and-patterns-of-failure
#3
Matthias Felix Haefner, Kristin Lang, Vivek Verma, Stefan Alexander Koerber, Lorenz Uhlmann, Juergen Debus, Florian Sterzing
PURPOSE: Randomized trials examining neoadjuvant chemoradiotherapy followed by surgical resection (nCRT-S) and definitive CRT (dCRT) for esophageal cancer (EC) patients are hampered by use of nonstandard treatment paradigms. Outcomes of nCRT-S versus dCRT in a more common patient population are lacking. We investigated local control and survival, evaluated clinical factors associated with endpoints, and assessed patterns of failure between these cohorts. METHODS: We retrospectively analyzed 130 patients with locally advanced EC receiving either dCRT or nCRT-S at our institution from 2000-2012...
September 15, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28915617/predictive-factors-of-pathologic-complete-response-in-her2-positive-and-axillary-lymph-node-positive-breast-cancer-after-neoadjuvant-paclitaxel-carboplatin-plus-with-trastuzumab
#4
Jinhua Ding, Yinlong Yang, Li Jiang, Weizhu Wu, Zhiming Shao
OBJECTIVE: This study was performed to investigate the proportion as well as the predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab (PCH). RESULTS: The pCR rate in the breast, axilla and both was 44.3% (39/88), 47.7% (42/88) and 34.1% (30/88), respectively. Patients with and without pCR were similar in term of age, BMI, menstrual status, family history, treatment cycles and tumor characteristics (laterality and size of tumor)...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915580/molecular-and-functional-characterization-of-a-new-3-end-kit-juxtamembrane-deletion-in-a-duodenal-gist-treated-with-neoadjuvant-imatinib
#5
Vittorio Perfetti, Erik Laurini, Suzana Aulić, Maurizio Fermeglia, Roberta Riboni, Marco Lucioni, Elena Dallera, Sara Delfanti, Luigi Pugliese, Francesco Saverio Latteri, Andrea Pietrabissa, Sabrina Pricl
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express the receptor tyrosine kinase KIT, and the majority of GISTs present KIT gain-of-function mutations that cluster in the 5' end of the receptor juxtamembrane domain. On the other hand, little information is known about GISTs carrying mutations in the 3' end of the KIT juxtamembrane domain. Here we report and discuss a clinical case of localized duodenal GIST whose molecular characterization revealed the presence of a new 21 nucleotide/7 amino acid deletion in the 3' end of KIT juxtamembrane domain (Δ574-580)...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28912413/-a-case-of-alcoholic-liver-disease-presenting-as-prominent-accumulation-of-ascites-associated-with-liver-damage-due-to-capeox
#6
Yoshikuni Yonenaga, Marika Nio, Yoshihiro Yata, Shunichi Higashide
A 75-year-old man with rectal cancer had consumed an average of6 6 g of alcohol per day for 47 years. However, his liver function was within normal limits and his Child-Pugh classification was A before initiation of therapy. He underwent neoadjuvant chemoradiation and a low anterior resection. The patient then received CapeOX as an adjuvant therapy. During the fourth cycle of CapeOX, computed tomography(CT)showed massive ascites. The chemotherapy was discontinued and treatment including a diuretic agent was initiated...
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28911922/neoadjuvant-sorafenib-gemcitabine-and-cisplatin-administration-preceding-cystectomy-in-patients-with-muscle-invasive-urothelial-bladder-carcinoma-an-open-label-single-arm-single-center-phase-2-study
#7
Andrea Necchi, Salvatore Lo Vullo, Daniele Raggi, Federica Perrone, Patrizia Giannatempo, Giuseppina Calareso, Elena Togliardi, Nicola Nicolai, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Maurizio Colecchia, Adele Busico, Marzia Pennati, Nadia Zaffaroni, Luigi Mariani, Roberto Salvioni
BACKGROUND: Outcomes of neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder carcinoma (MIUBC) should be improved. Sorafenib was combined with gemcitabine and cisplatin chemotherapy (SGC) in an open-label, single-arm, phase 2 trial (NCT01222676). PATIENTS AND METHODS: After transurethral resection of the bladder, T2-T4a N0 patients received four cycles of SGC followed by cystectomy. Sorafenib 400mg q12h daily, continuously, was added to standard GC chemotherapy...
September 11, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28911071/prediction-of-pathological-response-to-neoadjuvant-treatment-in-rectal-cancer-with-a-two-protein-immunohistochemical-score-derived-from-stromal-gene-profiling
#8
S Gonçalves-Ribeiro, R Sanz-Pamplona, A Vidal, X Sanjuan, N Guillen Díaz-Maroto, A Soriano, J Guardiola, N Albert, M Martínez-Villacampa, I López, C Santos, J Serra-Musach, R Salazar, G Capellà, A Villanueva, D G Molleví
Background: Preoperative chemoradiotherapy followed by surgical mesorectal resection is the standard of care for locally advanced rectal carcinomas. Yet, predicting that patients will respond to treatment remains an unmet clinical challenge. Experimental design: Using laser-capture microdissection we isolated RNA from stroma and tumour glands from prospective pre-treatment samples (n = 15). Transcriptomic profiles were obtained hybridising PrimeView Affymetrix arrays...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28911063/stromal-lymphocyte-infiltration-after-neoadjuvant-chemotherapy-is-associated-with-aggressive-residual-disease-and-lower-disease-free-survival-in-her2-positive-breast-cancer
#9
A-S Hamy, J-Y Pierga, A Sabaila, E Laas, H Bonsang-Kitzis, C Laurent, A Vincent-Salomon, P Cottu, F Lerebours, R Rouzier, M Lae, F Reyal
Background: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#10
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28905486/perioperative-allogeneic-blood-transfusion-does-not-adversely-impact-oncological-outcomes-after-radical-cystectomy-for-urinary-bladder-cancer-a-propensity-score-weighted-european-multicenter-study
#11
Malte W Vetterlein, Philipp Gild, Luis A Kluth, Thomas Seisen, Michael Gierth, Hans-Martin Fritsche, Maximilian Burger, Chris Protzel, Oliver W Hakenberg, Nicolas von Landenberg, Florian Roghmann, Joachim Noldus, Philipp Nuhn, Armin Pycha, Michael Rink, Felix K-H Chun, Matthias May, Margit Fisch, Atiqullah Aziz
OBJECTIVES: To evaluate the effect of perioperative blood transfusion (PBT) on recurrence-free survival (RFS), overall survival (OS), cancer-specific mortality (CSM), and other-cause mortality (OCM) in patients undergoing radical cystectomy (RC), utilizing a contemporary European multicenter cohort. PATIENTS AND METHODS: The PROspective MulticEnTer RadIcal Cystectomy Series (PROMETRICS) includes data on 679 patients who underwent RC at 18 European tertiary care centers in 2011...
September 14, 2017: BJU International
https://www.readbyqxmd.com/read/28901002/-current-research-status-and-progress-of-primary-esophageal-gastrointestinal-stromal-tumors-in-china
#12
Guoren Li, Jianhua Dai
Primary esophageal gastrointestinal stromal tumors (GIST) is a rare independent disease with clinicopathological and molecular features different from other mesenchymal tumors. Authors searched and reviewed associated reports and summarized the morbidity trends, characteristics, diagnosis and treatment of esophageal GIST in China. Data show that the incidence and detection rate of esophageal GIST presents the rising trend. Imaging has some characteristics. Ultrasonography and CT are main methods and effective examinations to detect and prompt diagnosis of esophageal GIST...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900290/alteration-of-pd-l1-expression-and-its-prognostic-impact-after-concurrent-chemoradiation-therapy-in-non-small-cell-lung-cancer-patients
#13
Daichi Fujimoto, Keiichiro Uehara, Yuki Sato, Ichiro Sakanoue, Munehiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Yasuhiro Kosaka, Kojiro Otsuka, Yukihiro Imai, Hiroshi Hamakawa, Yutaka Takahashi, Masaki Kokubo, Keisuke Tomii
Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD-1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CCRT on programmed cell death ligand-1 (PD-L1) expression on tumor cells is unknown. In this study, we analysed paired NSCLC specimens that had been obtained pre- and post-CCRT. PD-L1 expression on tumor cells was studied by immunohistochemistry...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28894581/positron-emission-tomography-computed-tomography-for-osseous-and-soft-tissue-sarcomas-a-systematic-review-of-the-literature-and-meta-analysis
#14
Aikeremujiang Muheremu, Junyi Ma, Aierken Amudong, Yong Ma, Maimaitiaili Niyazi, Yong Ou, Yuan Ma
In order to elucidate the value of positron emission tomography (PET)/computed tomography (CT) in the clinical diagnosis and treatment of osseous and soft tissue malignancies, two authors independently searched the PubMed, Medline, Elsevier, Embase and Cochrane Library databases for literature published between January 2003 and February 2016, using the key words 'PET/CT', 'positron emission tomography/computed tomography', 'osseous sarcoma', 'bone tumor', 'soft tissue sarcoma' and 'neoadjuvant', to identify prospective and retrospective studies on the applicability of PET/CT on the clinical diagnosis of bone and soft tissue lesions, and evaluation of their response to neoadjuvant therapies...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28894577/effects-of-neoadjuvant-chemotherapy-on-patients-with-primary-vaginal-squamous-cell-carcinoma
#15
Yuchao Diao, Jinwen Jiao, Kejuan Song, Lei Wang, Teng Lv, Shuzhen Dai, Qin Yao
Vaginal cancer is a rare gynecological malignancy, mainly treated by radiotherapy and surgery. However, the effect of neoadjuvant chemotherapy on patients with vaginal cancer has not been extensively evaluated. The aim of the present study was to assess the feasibility and efficacy of irinotecan and cisplatin in the management of patients with vaginal squamous cell cancer (SCC). Two patients with International Federation of Obstetrics and Gynecology (FIGO) stage I and one patient with FIGO stage II vaginal SCC were treated with irinotecan (240 mg) and cisplatin (100 mg) every 3-4 weeks...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28893901/expression-of-pd-l1-in-hormone-na%C3%A3-ve-and-treated-prostate-cancer%C3%A2-patients-receiving-neoadjuvant%C3%A2-abiraterone-acetate-plus-prednisone-and-leuprolide
#16
Carla Calagua, Joshua Russo, Yue Sun, Rachel Schaefer, Rosina Lis, Zhenwei Zhang, Kathleen M Mahoney, Glenn J Bubley, Massimo Loda, Mary-Ellen Taplin, Steven P Balk, Huihui Ye
PURPOSE: Programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) blockade has been unsuccessful in prostate cancer (PCa), with poor immunogenicity and subsequent low PD-L1 expression in PCa being proposed as an explanation. However, recent studies indicate that a subset of PCa may express significant levels of PD-L1. Further, the androgen antagonist enzalutamide has been shown to up-regulate PD-L1 expression in PCa preclinical models. In this study, we evaluated the effect of neoadjuvant androgen deprivation therapy with abiraterone acetate plus prednisone and leuprolide (Neo-AAPL) on PD-L1 expression in PCa...
September 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28893303/contrast-enhanced-spectral-mammography-in-neoadjuvant-chemotherapy-monitoring-a-comparison-with-breast-magnetic-resonance-imaging
#17
Valentina Iotti, Sara Ravaioli, Rita Vacondio, Chiara Coriani, Sabrina Caffarri, Roberto Sghedoni, Andrea Nitrosi, Moira Ragazzi, Elisa Gasparini, Cristina Masini, Giancarlo Bisagni, Giuseppe Falco, Guglielmo Ferrari, Luca Braglia, Alberto Del Prato, Ivana Malavolti, Vladimiro Ginocchi, Pierpaolo Pattacini
BACKGROUND: Neoadjuvant-chemotherapy (NAC) is considered the standard treatment for locally advanced breast carcinomas. Accurate assessment of disease response is fundamental to increase the chances of successful breast-conserving surgery and to avoid local recurrence. The purpose of this study was to compare contrast-enhanced spectral mammography (CESM) and contrast-enhanced-MRI (MRI) in the evaluation of tumor response to NAC. METHODS: This prospective study was approved by the institutional review board and written informed consent was obtained...
September 11, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28892901/invasive-ductal-carcinoma-breast-how-neoadjuvant-chemotherapy-affects-the-status-of-estrogen-receptor-progesterone-receptor-and-her2-neu-a-tertiary-care-centre-study
#18
Swasti Shubham, Pratibha Maan, Monika Singh, Minakshi Bhardwaj
INTRODUCTION: Determination of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2/neu in primary Invasive Ductal Carcinoma (IDC) breast is the standard of care parameter for determining treatment options. Whether or not Neoadjuvant Chemotherapy (NAC) affects the receptor status is still an unanswered question. AIM: To compare immunohistochemical (IHC) profiles of ER, PR and HER2/neu in primary IDC breast before and after NAC to assess the subsequent effects on receptor status...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28892579/elevated-expression-of-%C3%AE-np63-in-advanced-esophageal-squamous-cell-carcinoma
#19
Yuji Kumakura, Susumu Rokudai, Misaki Iijima, Bolag Altan, Tomonori Yoshida, Halin Bao, Takehiko Yokobori, Makoto Sakai, Makoto Sohda, Tatsuya Miyazaki, Masahiko Nishiyama, Hiroyuki Kuwano
This study aims to explore the expression level of ΔNp63 in esophageal squamous cell carcinoma (ESCC). To investigate the association between ΔNp63 (p40) expression and ESCC biology, we compared the levels of ΔNp63 expression in normal and tumor tissues, with a specific focus on the diagnostic value of ΔNp63 in ESCC. We analyzed 160 consecutive patients with ESCC who underwent surgical resection without neoadjuvant-chemotherapy at Gunma University Hospital between September 2000 and January 2010. The clinicopathological characteristics and survival of patients were subclassified based on the expression of ΔNp63 as determined by immunohistochemistry, demonstrating that ΔNp63 was highly expressed in 75...
September 11, 2017: Cancer Science
https://www.readbyqxmd.com/read/28890819/the-role-of-induction-chemotherapy-chemoradiotherapy-in-localised-pancreatic-cancer-initial-experience-in-scotland
#20
Derek Grose, David McIntosh, Nigel Jamieson, Ross Carter, Euan Dickson, David Chang, Husam Marashi, Christina Wilson, Mohammed Alfayez, Ashleigh Kerr, Roisin O'Donoghue, Lea Haskins, Fraser Duthie, Colin J McKay, Janet Graham
BACKGROUND: Despite being relatively rare pancreatic cancer is one of the highest causes of death. Even within the potentially resectable group outcomes are poor. We present our initial experiences utilising a neoadjuvant approach to localised pancreatic cancer, evaluating survival, response rates and tolerability. METHODS: This was a retrospective analysis of a prospectively maintained database. Patients from 2012 to 2015 referred to a busy regional Hepato-Pancreatic Biliary (HPB) MDT were included...
August 2017: Journal of Gastrointestinal Oncology
keyword
keyword
50051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"